Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
HAYWARD, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, is pleased to announce the publication of a landmark study in The New England Journal of...
-
PredicineCARE™ was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing to the FDA’s approval of Inavolisib in the U.S. on...
-
HAYWARD, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 9 ctDNA studies at ASCO 2024,...
-
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
-
Collaboration Utilizing PredicineCARE™ Blood cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
-
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
-
HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting...
-
Collaboration Utilizing PredicineCARE™ Urine cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
-
HAYWARD, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced a significant clinical milestone with the new publication of Genentech’s Divarasib...
-
HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid,...